# A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

> **NCT06759649** · PHASE1 · RECRUITING · sponsor: **Compugen Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Neoplasm
- Cancer, Malignant Tumors

## Interventions

- **DRUG:** COM503
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT06759649
- **Lead sponsor:** Compugen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2027-11-22
- **Final completion:** 2027-11-22
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759649, "A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06759649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*